Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

NCT ID: NCT05035745

Last Updated: 2025-07-25

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-01
• Study Completion Date: 2027-11-30

Brief Summary

This is a single arm, open-label, phase I dose finding study, followed by a phase II expansion study. Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of 33 patients with refractory solid tumors to determine the RP2D. In the phase II portion, a total of 30 patients with advanced/metastatic TNBC will be enrolled.

Detailed Description

Hypothesis The investigators hypothesize that the combination of Talazoparib and Selinexor will have clinical efficacy in TNBC, independent of BRCA mutation status.

Primary Objectives

• To determine the safety profile of combination of Talazoparib and Selinexor in advanced/ metastatic solid tumors.
• To determine the RP2D of Talazoparib and Selinexor combination therapy in patients with advanced/ metastatic solid tumors.

Secondary Objectives

• To determine the objective response rate to combination Talazoparib and Selinexor in advanced/ metastatic TNBCs.

Exploratory Objectives

• To assess the effect of the combination on pharmacokinetics of Talazoparib and Selinexor
• To explore the impact of pharmacogenetics on toxicity and efficacy of combination Talazoparib and Selinexor.
• To assess changes in circulating tumor cells and plasma biomarkers during treatment.
• To assess pharmacodynamic changes and predictive biomarkers in tumor tissue during treatment.

Conditions

Advanced Refractory Solid Tumors; Advanced Triple Negative Breast Cancers; Metastatic Triple Negative Breast Cancers

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Patients with refractory solid tumors

Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of patients with refractory solid tumors to determine the RP2D.

Group Type: EXPERIMENTAL

Talazoparib

Intervention Type: DRUG

Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)

Selinexor

Intervention Type: DRUG

Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)

Interventions

Talazoparib

Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)

Intervention Type: DRUG

Selinexor

Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. All patients must sign an informed consent in accordance with local institutional guidelines.

2. All patient must not have received prior PARPi including talazoparib

3. All patients must not have prior therapy with selinexor.

4. Age ≥ 18

5. Estimated life expectancy of at least 12 weeks.

6. Has recovered from acute toxicities from prior anti-cancer therapies to grade 2 or lower.

7. a) Dose escalation phase: Patients with histologically or cytologically confirmed advanced or metastatic solid tumors who have radiological evidence of progressive disease on study entry that is deemed unlikely to benefit from further conventional therapy, or for which no standard therapy is available.

b) Dose expansion phase: Patients with previously treated, advanced or metastatic histologically or cytologically confirmed triple negative breast cancers. Patients must have evidence of progressive disease on study entry after at least one line of anti-cancer therapy. Patients will be stratified into platinum-naïve (not having been treated with platinums-containing chemotherapy in the neoadjuvant, adjuvant or palliative setting), platinum sensitive (defined as having prior objective response or sustained disease control lasting ≥6 months to platinum-containing chemotherapy in the metastatic setting, or relapsed ≥6 months after completing neoadjuvant or adjuvant platinums-containing chemotherapy), and platinum resistant (defined as having progressive disease as the best response or disease control <6 months to platinum-containing chemotherapy in the metastatic setting, or relapsed <6 months after completing neoadjuvant or adjuvant platinums-containing chemotherapy).

Exclusion Criteria

8. Measurable disease by RECIST 1.1 criteria.

9. Eastern cooperative Oncology Group (ECOG) Performance Status of 0-1

10. Adequate bone marrow function and organ function within 2 weeks of study treatment

1. Adequate hematologic function defined as:

• Absolute neutrophil (segmented and bands) count (ANC) ≥ 1.5 x 109/L
• Platelets ≥ 125 x 109/L during dose escalation phase; platelets ≥ 100 x 109/L during dose expansion phase
• Hemoglobin ≥ 9 x 109/L

2. Hepatic function:

• Bilirubin ≤ 1.5 times the upper limit of normal (ULN)
• ALT or AST ≤ 2.5 times ULN (or ≤ 5 times ULN with liver metastases)

3. Adequate renal function:

• Calculated creatinine clearance of ≥ 60 mL/min, calculated using the formula of Cockroft and Gault: (140-Age) x Mass (kg)/(72 x creatinine mg/dL); multiply by 0.85 if female.

11. Able to swallow tablets/ pills.

12. Able to comply with study-related procedures.

13. Female patients of childbearing potential must have a negative serum pregnancy test at screening and agree to use highly effective methods of contraception throughout the study and for 7 months following the last dose of study treatment

1. Treatment within the last 30 days with any investigational drug.

2. Concurrent administration of any other tumour therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy

3. Major surgery within 28 days of study drug administration

4. Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.

5. Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.

6. Pregnancy

7. Breast feeding

8. Poorly controlled diabetes mellitus

9. Second primary malignancy that is clinically detectable at the time of consideration for study enrolment (for phase II only).

10. Symptomatic brain metastasis.

11. History of significant neurological or mental disorder, including seizures or dementia.

12. Unable to comply with study procedures

13. Current or anticipated use of strong P-gp inhibitors: amiodarone, carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, valspodar, verapamil

14. Current or anticipated use of strong BCRP inhibitors: curcumin, cyclosporine A, eltrombopag, elacridar, fumitremorgin C, novobiocin, sulfasalazine

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National University Hospital, Singapore

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Soo Chin Lee

Role: PRINCIPAL_INVESTIGATOR

National University Hospital, Singapore

Locations

National University Hospital

Singapore, , Singapore

Site Status: RECRUITING

Countries

Singapore

Central Contacts

Soo Chin Lee

Role: CONTACT

soo_chin_lee@nuhs.edu.sg

6779 5555

Facility Contacts

Dr

Role: primary

References

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.

Reference Type: BACKGROUND

PMID: 30345906 (View on PubMed)

Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. doi: 10.1093/annonc/mdz012.

Reference Type: BACKGROUND

PMID: 30689707 (View on PubMed)

Other Identifiers

MC01/05/20; IST-325 (KPT)

Identifier Type: -

Identifier Source: org_study_id